ArticleInvestigative ophthalmology & visual science2026
Novel Inositol Acyltransferase (Gwt1) Inhibitor for Fungal Keratitis Treatment: Evaluation of In Vitro and In Vivo Efficacy and Safety.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Fungal keratitis (FK) is a vision-threatening infection affecting ∼1 million people annually. This study assesses the therapeutic potential of Manogepix (MGX), a first-in-class Gwt1 fungal enzyme inhibitor, using in vitro and in vivo models. Methods: MGX's in vitro efficacy was evaluated against clinical keratitis isolates of Candida albicans (n = 10), Fusarium solani (n = 8), and Aspergillus flavus (n = 6) by determining minimal inhibitory and fungicidal concentrations (MIC and MFC), biofilm inhibition, morphological changes, time-kill kinetics at MIC and interaction with amphotericin B. Safety was assessed in vitro on human corneal epithelial cells (HCECs) and in vivo via Draize's test. In vivo efficacy was evaluated in a rabbit F. solani keratitis model. Animals received topical MGX (50 µL, 0.01% w/v, 8×/day) for four days, followed by clinical scoring, colony-forming unit (CFU) enumeration, and histopathological analysis. Results: MGX was fungicidal against C. albicans (MIC₉₀: 0.0313, MFC₉₀: 0.156 µg/mL) and fungistatic against F. solani and A. flavus, with IC₈₀ ranges of 0.019-0.312 and 1.25-20 µg/mL, respectively. At MIC and IC80, MGX inhibited biofilm formation, disrupted fungal cellular morphology and proliferation dynamics. MGX exhibited synergistic/additive effects with amphotericin B. MGX was found safe in vitro at 5 µg/mL on HCECs and showed no signs of corneal toxicity in vivo at 100 µg/mL. In the rabbit model F. solani keratitis, MGX treatment reduced the clinical manifestations of FK and significantly reduced CFU counts compared with untreated controls. Conclusions: MGX demonstrated efficacy against major ocular fungal pathogens and showed a favorable ocular safety profile in both in vitro and in vivo models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.